Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.
Shanghai Junshi Biosciences Co., Ltd. announced the successful conclusion of its 2024 Annual General Meeting (AGM), where all proposed resolutions were passed. The AGM, held on June 20, 2025, saw participation from shareholders representing a significant portion of the company’s shares. Key resolutions included the approval of the 2024 financial reports, profit distribution plan, and the appointment of auditors for 2025. The results reflect strong shareholder support and are expected to positively impact the company’s strategic operations and financial planning.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biotechnology company based in China, primarily focused on the research, development, and commercialization of innovative drugs. The company is active in the pharmaceutical industry, with a market focus on creating therapies for cancer, autoimmune, and metabolic diseases.
Average Trading Volume: 5,791,608
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.7B
For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.